DEXCOM INC 4

Kevin R. Sayer, Executive Chair of Dexcom, Inc., sold 26,756 shares of common stock for about $2.0 million under a Rule 10b5-1 plan.

On July 20, 2026, Kevin R. Sayer, Executive Chair of Dexcom, Inc., sold 26,756 shares of Dexcom common stock at a weighted average price of $76.3193 per share, for total proceeds of approximately $2.04 million. The sale was reported as a disposition of directly held shares and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2026, with individual trade prices ranging from $75.80 to $76.62. Following this transaction, Sayer reported direct ownership of 328,970 shares of Dexcom common stock, a figure that includes 106,972 unvested restricted stock units scheduled to vest between 2024 and 2028, implying an estimated post-transaction equity position of roughly $25.1 million based on the reported sale price.

Filing Facts

CIK

1093557

Ticker

DXCM

Form

4

Source Type

sec

Accession

0001093557-26-000137

Alert Tier

7